

해외 바이오의약품 임상 현황 ('23년 6월 4주)

한국바이오의약품협회, 2023.07.04.

※ ClinicalTrials.gov에 등록된 국가별 바이오의약품 임상시험 목록(병용요법 포함)을 한국바이오의약품협회에서 주간 업데이트하여 제공합니다.

URL을 클릭하시면 세부 정보 페이지로 연결됩니다.

- 출처: ClinicalTrials.gov

모니터링 기간: 2023.06.26.~2023.07.02.

- 주간 업데이트 제공국가 : 미국, 유럽(영국, 프랑스, 독일), 중국, 일본

○ 미국 86건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05914116	A Study of DB-1311 in Advanced/Metastatic Solid Tumors	Drug: DB-1311	DualityBio Inc.	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05914116
NCT05848687	TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II	Drug: Dexamethasone Drug: Mitoxantrone Drug: PEG asparaginase Drug: Bortezomib Drug: Vorinostat Drug: Mercaptopurine Drug: Methotrexate Drug: Blinatumomab Drug: Ziftomenib	Stanford University Pediatric Oncology Experimental Therapeutics Investigators' Consortium Amgen Lucile Packard Children's Hospital Foundation	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05848687
NCT05845749	Safety and Efficacy of Voxzogo for Growth Deficits in MPS IVA and VI	Drug: Vosoritide Injection [Voxzogo]	UCSF Benioff Children's Hospital Oakland	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05845749
NCT05756166	Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer	Procedure: Biopsy Procedure: Biospecimen Collection Drug: Celecoxib Procedure: Computed Tomography Biological: Interferon Alpha-2 Procedure: Magnetic Resonance Imaging Biological: Pembrolizumab Drug: Rintatolimod	Roswell Park Cancer Institute	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05756166
NCT05687721	Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer	Drug: copanlisib Drug: Avelumab	VA Office of Research and Development Bayer	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05687721
NCT05627635	FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer	Biological: Balstilimab Biological: Bevacizumab Procedure: Biospecimen Collection Biological: Botensilimab Procedure: Computed Tomography Drug: Fluorouracil Drug: Leucovorin Calcium Procedure: Magnetic Resonance Imaging Drug: Oxaliplatin Procedure: Positron Emission Tomography Procedure: X-Ray Imaging	City of Hope Medical Center National Cancer Institute (NCI)	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05627635
NCT05559879	Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma	Drug: Cabo + Dostarlimab	University of Alabama at Birmingham	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05559879
NCT05110742	Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignancies	Drug: Fludarabine Phosphate Drug: Cyclophosphamide Drug: CAR.5/IL15-transduced CB-NK cells	M.D. Anderson Cancer Center	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05110742
NCT05929664	Cemiplimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before Surgery	Biological: Cemiplimab Procedure: Computed Tomography Procedure: Biospecimen Collection Other: Quality-of-Life Assessment	Thomas Jefferson University	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05929664

해외 바이오의약품 임상 현황 ('23년 6월 4주)

한국바이오의약품협회, 2023.07.04.

○ 미국 86건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05910528	RVT-3101 for the Treatment of Moderate to Severe Active Crohn's Disease	Drug: RVT-3101	Telavant, Inc.	Phase 2	
NCT05901545	Evaluating 111In Panitumumab for Nodal Staging in Head and Neck Cancer	Biological: Panitumumab Other: Indium In 111 Panitumumab Procedure: Single Photon Emission Computed Tomography Procedure: Computed Tomography Procedure: Surgical Procedure Other: Imaging agent Procedure: Intraoperative Imaging Procedure: Near Infrared Imaging Procedure: Electrocardiography Procedure: Biospecimen Collection	Vanderbilt-Ingram Cancer Center American Cancer Society, Inc.	Phase 1	
NCT05901467	Recall by Genotype: Neuropeptide Stimulation	Drug: kisspeptin 112-121 Drug: GnRH	Stephanie B. Seminara, MD Massachusetts General Hospital	Phase 1	
NCT05901285	Phase 1 Study of Intratumoral Administration of VAX014 in Subjects With Advanced Solid Tumors	Drug: VAX014	Vaxiion Therapeutics	Phase 1	
NCT05892393	Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma	Drug: Zirconium Zr 89-DFO-YS5 Procedure: Positron Emission Tomography / Computed Tomography (PET/CT) Procedure: Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI) Other: Fludeoxyglucose F-18	Robert Flavell, MD, PhD National Cancer Institute (NCI) University of California, San Francisco	Phase 1	
NCT05891236	Safety, Tolerability, Pharmacokinetics and Protective Efficacy of MAM01 in Healthy Adults	Biological: MAM01 Biological: Placebo	Bill & Melinda Gates Medical Research Institute	Phase 1	
NCT05887882	Intra-Tumoral Injections of Natural Killer Cells for Recurrent Malignant Brain Tumors	Biological: Universal Donor (UD) Transforming growth factor beta imprinting (TGFβi) Natural Killer (NK) Cells Procedure: Implantation	Sabine Mueller, MD, PhD Rally Foundation Washington University School of Medicine Nationwide Children's Hospital University of California, San Francisco	Phase 1	
NCT05881408	A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of SRP-9001 (Delandistrogene Moxeparvovec) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)	Genetic: SRP-9001 Genetic: Placebo	Sarepta Therapeutics, Inc. Hoffmann-La Roche	Phase 3	
NCT05873712	Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome	Procedure: Biospecimen Collection Procedure: Bone Marrow Biopsy Procedure: Computed Tomography Drug: Cyclophosphamide Drug: Fludarabine Procedure: Leukapheresis Biological: Lisocabtagene Maraleucel Procedure: Lymph Node Biopsy Procedure: Positron Emission Tomography Drug: Zanubrutinib	Adam Kittai Ohio State University Comprehensive Cancer Center	Phase 2	

해외 바이오의약품 임상 현황 ('23년 6월 4주)

한국바이오의약품협회, 2023.07.04.

○ 미국 86건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05870761	Combination Niraparib and Dostarlimab Therapy for Recurrent or Persistent Uterine Serous Carcinoma	Procedure: Biospecimen Collection Procedure: Computed Tomography Biological: Dostarlimab Procedure: Magnetic Resonance Imaging Drug: Niraparib	Casey Cosgrove Ohio State University Comprehensive Cancer Center	Phase 2	
NCT05868499	Rollover Study From EXG-US-01	Biological: EXG34217	Elixirgen Therapeutics, Inc.	Phase 1	
NCT05854966	CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)	Drug: CPI 613 Drug: Metformin Biological: Blood draws Procedure: Bone marrow biopsy	Wake Forest University Health Sciences National Cancer Institute (NCI) Cornerstone Pharmaceuticals	Phase 2	
NCT05854498	Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer	Drug: Liposomal irinotecan Drug: TAS102 Drug: Bevacizumab	University of Wisconsin, Madison Ipsen	Phase 2	
NCT05814666	Activity and Safety of Danvatirsén and Pembrolizumab in HNSCC	Drug: Danvatirsén Drug: Pembrolizumab	Flamingo Therapeutics NV	Phase 2	
NCT05802056	Aldesleukin in Combination With Nivolumab and Standard Chemotherapy for the Treatment of Gastric Cancer With Peritoneal Metastasis, CONTROL Study	Biological: Aldesleukin Procedure: Biopsy Procedure: Biospecimen Collection Procedure: Computed Tomography Procedure: Diagnostic Laparoscopy Drug: Fluorouracil Drug: Leucovorin Calcium Procedure: Magnetic Resonance Imaging Biological: Nivolumab Drug: Oxaliplatin Procedure: Positron Emission Tomography	Mayo Clinic	Phase 1	
NCT05801939	Cevostamab Following CAR T Cell Therapy for RRMM	Drug: Cevostamab	University of Pennsylvania Genentech, Inc.	Phase 2	
NCT05794958	Evaluate Safety of Axicabtagene CiloleuceL Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel	Drug: Axicabtagene CiloleuceL	Stanford University Kite Pharma	Phase 1	
NCT05789303	Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma	Drug: Belantamab mafodotin Drug: Carfilzomib Drug: Pomalidomide Drug: Dexamethasone	University of Chicago GlaxoSmithKline Amgen	Phase 2	
NCT05785754	DCSZ11 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors	Drug: DCSZ11	DynamiCure Biotechnology	Phase 1	
NCT05783596	Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma	Drug: Obinutuzumab Drug: Glofitamab	Reid Merryman, MD Genentech, Inc. Dana-Farber Cancer Institute	Phase 2	
NCT05766371	Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer	Drug: Pembrolizumab Drug: 177Lu-PSMA-617	University of California, San Francisco Merck Sharp & Dohme LLC Prostate Cancer Foundation	Phase 2	

해외 바이오의약품 임상 현황 ('23년 6월 4주)

한국바이오의약품협회, 2023.07.04.

○ 미국 86건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05757310	A Reduced-Intensity Conditioning Regimen (Cyclophosphamide, Pentostatin, Anti-thymocyte Globulin) Followed by Haploidentical Hematopoietic Stem Cell Transplant for the Treatment of Patients With Refractory or Recurrent Severe Aplastic Anemia	Biological: Anti-Thymocyte Globulin Procedure: Biospecimen Collection Procedure: Bone Marrow Aspirate Procedure: Bone Marrow Biopsy Drug: Cyclophosphamide Procedure: Haploidentical Hematopoietic Cell Transplantation Drug: Pentostatin Other: Questionnaire Administration	City of Hope Medical Center National Cancer Institute (NCI)	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05757310
NCT05746208	Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors	Drug: Lenvatinib Drug: Pembrolizumab Drug: Hyperpolarized 13C-Pyruvate	University of California, San Francisco Merck Sharp & Dohme LLC	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05746208
NCT05743595	Neoantigen-based Personalized DNA Vaccine With Retifanimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma	Biological: Personalized Neoantigen DNA vaccine Biological: Retifanimab Device: TDS-IM v 2.0 electroporation device	Washington University School of Medicine Incyte Corporation Ichor Medical Systems Incorporated	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05743595
NCT05741164	Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer	Procedure: Biopsy Procedure: Biospecimen Collection Procedure: Computed Tomography Biological: Pembrolizumab Drug: Propranolol Other: Questionnaire Administration	Roswell Park Cancer Institute	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05741164
NCT05727384	Improving Physical Function in Older Adults Using an Anti-inflammation Drug: The RIGHT Study	Drug: Clazakizumab Drug: Placebo	Anne B. Newman CSL Behring University of Pittsburgh	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05727384
NCT05726396	A Pilot Study Testing the Safety and Feasibility of Restorative Microbiota Therapy (RMT) in Patients With Refractory Immune-checkpoint Inhibitor-related Colitis	Drug: RMT Drug: Placebo	University of Minnesota	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05726396
NCT05724134	Pancreatic Clamp in NAFLD	Drug: Insulin human Drug: Octreotide Acetate Drug: Glucagon Drug: Growth Hormone, Human Other: [6,6-2H2] D-glucose Drug: 20% D-glucose (aq) Dietary Supplement: BOOST Plus Device: Harvard Apparatus PHD ULTRA CP syringe pump Device: Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer	Columbia University Albert Einstein College of Medicine	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05724134
NCT05696782	Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer	Drug: Durvalumab Other: the EORTC Core Quality of Life Questionnaire (EORTC QLQ-C30) Diagnostic Test: COPD Assessment Test (CAT) Diagnostic Test: Modified Medical Research Council (mMRC) dyspnea scale	Wake Forest University Health Sciences	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05696782
NCT05690984	Elimination of Minimal Residual Disease After Transplant	Drug: Dexamethasone Drug: Isatuximab Drug: Lenalidomide	Medical College of Wisconsin	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05690984
NCT05675722	Implantation Of Vaginal Construct For Patients With Vaginal Aplasia	Biological: biologic vaginal-construct implantation	Wake Forest University Health Sciences	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05675722

해외 바이오의약품 임상 현황 ('23년 6월 4주)

한국바이오의약품협회, 2023.07.04.

○ 미국 86건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05664126	Haplo-identical Viral-Specific T-cells for Treatment of Cytomegalovirus and Adenovirus Infections After Hematopoietic Cell Transplantation	Drug: VST infusion Device: CliniMACS	St. Jude Children's Research Hospital	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05664126
NCT05664113	Feasibility, Safety, and Potential Efficacy of Fecal Microbiota Transplantation (FMT) for Gastrointestinal Dysfunction in Children Following Hematopoietic Cell Transplant (HCT).	Drug: Fecal microbiota transplant (FMT)	St. Jude Children's Research Hospital	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05664113
NCT05654506	Daratumumab for Treatment of Proliferative Glomerulonephritis With Monoclonal Immune Deposits	Drug: Daratumumab	Mayo Clinic	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05654506
NCT05629546	Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors	Biological: Memory-like natural killer cells Biological: Relatlimab Biological: Nivolumab	Washington University School of Medicine	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05629546
NCT05625594	Intracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes) for the Treatment of Primary Central Nervous System Lymphoma	Procedure: Aspiration Procedure: Biospecimen Collection Procedure: Catheterization Biological: CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes Procedure: Computed Tomography Drug: Cyclophosphamide Drug: Fludarabine Procedure: Leukapheresis Procedure: Lumbar Puncture Procedure: Magnetic Resonance Imaging Procedure: Positron Emission Tomography	City of Hope Medical Center National Cancer Institute (NCI)	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05625594
NCT05618301	Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD)	Drug: Motixafortide Drug: Natalizumab Procedure: Leukapheresis	Washington University School of Medicine BioLineRx, Ltd. Biogen	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05618301
NCT05609994	ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas	Drug: PEPIDH1M vaccine + vorasidenib	Katy Peters, MD, PhD Servier Duke University	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05609994
NCT05583708	Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer	Drug: Pembrolizumab Drug: Lutetium Lu 177 dotatate	Weill Medical College of Cornell University	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05583708
NCT05558982	BXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma	Drug: BXCL701 Drug: Pembrolizumab	Georgetown University BioXcel Therapeutics Inc Merck Sharp & Dohme LLC	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05558982
NCT05537402	LOcoregional vs Systemic Therapy in Patients With BCLC Stage B HCC (LOST- B) Trial	Drug: Atezolizumab and bevacizumab Radiation: transarterial chemoembolization (TACE) or transarterial radioembolization (TARE)	University of Texas Southwestern Medical Center Genentech, Inc.	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05537402
NCT05424003	Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant	Drug: Semaglutide Pen Injector Drug: Placebo	Virginia Commonwealth University Novo Nordisk A/S	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05424003

해외 바이오의약품 임상 현황 ('23년 6월 4주)

한국바이오의약품협회, 2023.07.04.

○ 미국 86건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05389423	Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas	Drug: Vincristine Drug: Prednisone Drug: Doxorubicin Drug: Etoposide Drug: Pomalidomide Drug: Cyclophosphamide Drug: Rituximab	National Cancer Institute (NCI) National Institutes of Health Clinical Center (CC)	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05389423
NCT05353530	Phase I Study of IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ and MGMT-unmethylated Adult Glioblastoma (IMPACT)	Biological: Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells	University of Florida United States Department of Defense AM Rosen Foundation	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05353530
NCT05161533	Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT Trial	Drug: Carboplatin Drug: Cisplatin Biological: Durvalumab Drug: Etoposide Radiation: Hypofractionated Radiation Therapy Other: Quality-of-Life Assessment Other: Questionnaire Administration	University of Washington AstraZeneca	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05161533
NCT05067595	Fecal Microbiota Transplant and Dietary Fiber Supplementation for the Treatment of Gut Graft Versus Host Disease	Procedure: Colonoscopy Biological: Fecal Microbiota Transplantation Dietary Supplement: Nutritional Supplementation Other: Survey Administration	Fred Hutchinson Cancer Center	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05067595
NCT05010564	Trivalent CAR-T Cell in Acute B-Lineage Leukemia (TRICAR-ALL)	Genetic: Autologous TRICAR-ALL T-cells and lymphodepletion chemotherapy	Baylor College of Medicine Texas Children's Cancer Center	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05010564
NCT04987996	GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients	Drug: GR-MD-02 Drug: Placebo Drug: Pembrolizumab	Providence Health & Services Providence Cancer Center, Earle A. Chiles Research Institute	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT04987996
NCT04466475	Radioimmunotherapy (211At-OKT10-B10) and Chemotherapy (Melphalan) Before Stem Cell Transplantation for the Treatment of Multiple Myeloma	Biological: Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10 Drug: Melphalan Procedure: Peripheral Blood Stem Cell Transplantation	Fred Hutchinson Cancer Center National Cancer Institute (NCI) National Institutes of Health (NIH)	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT04466475
NCT03913117	Study of Treatment for HPV16+ ASC-US or LSIL	Biological: pNGVL4aCRTE6E7L2 Biological: TA-CIN	University of Alabama at Birmingham Johns Hopkins University	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT03913117
NCT05800366	A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma	Drug: Glofitamab Drug: Polatuzumab Drug: Rituximab Drug: Doxorubicin Hydrochloride Drug: Cyclophosphamide Drug: Prednisone	Philippe Armand, MD, PhD Genentech, Inc. Dana-Farber Cancer Institute	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05800366
NCT05726370	Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC	Drug: Pembrolizumab Drug: CISPLATIN Drug: Carboplatin Drug: Docetaxel	Dana-Farber Cancer Institute Merck Sharp & Dohme LLC	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05726370
NCT05706116	Controlled Human Infection Study of Orally Administered Trichuris Trichiura Eggs in Native Adults	Biological: Trichuris trichiura Egg Inoculum	George Washington University National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05706116
NCT05231122	Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer	Biological: Anti-CD40 Agonist Monoclonal Antibody CDX-1140 Biological: Bevacizumab Biological: Pembrolizumab Other: Quality-of-Life Assessment Other: Questionnaire Administration	Roswell Park Cancer Institute National Cancer Institute (NCI) Merck Sharp & Dohme LLC Celldex Therapeutics	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05231122

해외 바이오의약품 임상 현황 ('23년 6월 4주)

한국바이오의약품협회, 2023.07.04.

○ 미국 86건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT04563520	SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis	Drug: aPCC-emicizumab Drug: FEIBA Drug: rFVIIa	Emory University Takeda Pharmaceuticals North America, Inc.	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT04563520
NCT03258658	Safety and Feasibility Study of Autologous Engineered Urethral Constructs for the Treatment of Strictures	Biological: Autologous Engineered Urethral Construct	Wake Forest University Health Sciences United States Department of Defense	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT03258658
NCT05911321	Isa-Pom-Dex in Elderly/Frail Subjects With RRMM	Drug: Isatuximab Drug: Pomalidomide Drug: Dexamethasone	UNC Lineberger Comprehensive Cancer Center Genzyme, a Sanofi Company	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05911321
NCT05898646	Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial	Procedure: Bone Marrow Biopsy Biological: Daratumumab Procedure: Echocardiography Other: Questionnaire Administration Procedure: X-Ray Imaging	Mayo Clinic	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05898646
NCT05859464	A Phase 1 Study of ZL-1218 in Subjects With Advanced Solid Tumors	Drug: ZL-1218 Drug: Pembrolizumab	Zai Lab (Hong Kong), Ltd. Zai Biopharmaceutical (Suzhou) Co., Ltd. Merck Sharp & Dohme LLC	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05859464
NCT05479045	A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients	Biological: NY-ESO-1 Peptide vaccine Drug: Nivolumab	Georgetown University United States Department of Defense Bristol-Myers Squibb	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05479045
NCT05916560	A Study of LY3437943 in Participants With Impaired and Normal Liver Function	Drug: LY3437943	Eli Lilly and Company	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05916560
NCT05567835	A Study of Total Neoadjuvant Chemotherapy With FLOT VS Standard Perioperative FLOT in Patients With Gastric or GEJ Cancer	Drug: Fluorouracil Drug: Leucovorin Drug: Oxaliplatin Drug: Docetaxel Biological: GSCF	Baylor College of Medicine	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05567835
NCT05564598	CMV CTLs in Neonates With CMV Infection	Biological: CMV Cytotoxic T-Lymphocytes Drug: Anti-viral Therapy	New York Medical College	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05564598
NCT05194293	Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer	Biological: Durvalumab Drug: Regorafenib	Academic and Community Cancer Research United National Cancer Institute (NCI)	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05194293
NCT05079451	Broadly Neutralizing Antibodies 3BNC117-LS & 10-1074-LS to Prevent Relapse During ATI	Drug: 3BNC117-LS Drug: 10-1074-LS	National Institute of Allergy and Infectious Diseases (NIAID) Rockefeller University	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05079451
NCT05199688	A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)	Drug: Satralizumab	Hoffmann-La Roche	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05199688

해외 바이오의약품 임상 현황 ('23년 6월 4주)

한국바이오의약품협회, 2023.07.04.

○ 미국 86건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05470140	A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)	Biological: WU-NK-101	Wugen, Inc.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05470140
NCT05642455	SPEARHEAD-3 Pediatric Study	Genetic: Afamitresgene autoleucel	Adaptimmune	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05642455
NCT04046107	Safety and Immunotherapeutic Activity of Cemiplimab in Participants With HBV on Suppressive Antiviral Therapy	Biological: Cemiplimab	National Institute of Allergy and Infectious Diseases (NIAID) Regeneron Pharmaceuticals	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT04046107
NCT05917522	Assessment of Biomarker-Guided CNI Substitution In Kidney Transplantation	Biological: Abatacept Procedure: Standard of Care at US Transplant Centers	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05917522
NCT05878938	A Research Study Looking at How Safe it is to Switch From Emicizumab to Mim8 in People With Haemophilia A (FRONTIER 5)	Drug: NNC0365-3769 (Mim8) PPX	Novo Nordisk A/S	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05878938
NCT05733611	RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC	Biological: RP2 Biological: RP3 Biological: atezolizumab Biological: bevacizumab	Replimune Inc. Roche Pharma AG	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05733611
NCT05671510	Study of Gotistobart (ONC-392/BNT316) vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer	Drug: Gotistobart Drug: Docetaxel	OncoC4, Inc. BioNTech SE	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05671510
NCT05601752	ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)	Genetic: Autologous genetically modified ADP-A2M4CD8 cells Combination Product: Autologous genetically modified ADP-A2M4CD8 cells in combination with Nivolumab	Adaptimmune GOG Foundation	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05601752
NCT05873205	Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation	Biological: Isatuximab	Memorial Sloan Kettering Cancer Center Sanofi	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05873205
NCT05904496	A Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-30813	Drug: BGB-30813 Drug: Tislelizumab	BeiGene	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05904496

○ 영국 5건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05878938	A Research Study Looking at How Safe it is to Switch From Emicizumab to Mim8 in People With Haemophilia A (FRONTIER 5)	Drug: NNC0365-3769 (Mim8) PPX	Novo Nordisk A/S	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05878938
NCT05601752	ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)	Genetic: Autologous genetically modified ADP-A2M4CD8 cells Combination Product: Autologous genetically modified ADP-A2M4CD8 cells in combination with Nivolumab	Adaptimmune GOG Foundation	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05601752

해외 바이오의약품 임상 현황 ('23년 6월 4주)

한국바이오의약품협회, 2023.07.04.

○ 영국 5건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05718297	Brigatinib Post Definitive Chemo-radiotherapy in Patients With ALK-fusion Non-small Cell Lung Cancer	Drug: Brigatinib Drug: Durvalumab	ETOP IBCSG Partners Foundation Takeda	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05718297
NCT05199688	A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)	Drug: Satralizumab	Hoffmann-La Roche	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05199688
NCT05733611	RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC	Biological: RP2 Biological: RP3 Biological: atezolizumab Biological: bevacizumab	Replimune Inc. Roche Pharma AG	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05733611

○ 프랑스 6건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05545384	Immediate Versus Delayed Treatment With Azathioprine or Rituximab in Anti-MOG Antibodies Associated Acute Demyelinating Syndromes in Children: a Randomized Controlled Clinical Trial	Drug: Immediate Azathioprine (1st attack) Drug: Immediate Rituximab (1st attack) Drug: Standard of care	Assistance Publique - Hôpitaux de Paris Institut National de la Santé Et de la Recherche Médicale, France	Phase 2 Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05545384
NCT05601752	ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)	Genetic: Autologous genetically modified ADP-A2M4CD8 cells Combination Product: Autologous genetically modified ADP-A2M4CD8 cells in combination with Nivolumab	Adaptimmune GOG Foundation	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05601752
NCT05718297	Brigatinib Post Definitive Chemo-radiotherapy in Patients With ALK-fusion Non-small Cell Lung Cancer	Drug: Brigatinib Drug: Durvalumab	ETOP IBCSG Partners Foundation Takeda	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05718297
NCT05733611	RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC	Biological: RP2 Biological: RP3 Biological: atezolizumab Biological: bevacizumab	Replimune Inc. Roche Pharma AG	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05733611
NCT05199688	A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)	Drug: Satralizumab	Hoffmann-La Roche	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05199688
NCT05878938	A Research Study Looking at How Safe it is to Switch From Emicizumab to Mim8 in People With Haemophilia A (FRONTIER 5)	Drug: NNC0365-3769 (Mim8) PPX	Novo Nordisk A/S	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05878938

○ 독일 5건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05836896	A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies	Genetic: MDC-CAR-BCMA001 (BCMA directed CAR T-cells)	Technische Universität Dresden German Cancer Research Center	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05836896

해외 바이오의약품 임상 현황 ('23년 6월 4주)

한국바이오의약품협회, 2023.07.04.

○ 독일 5건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05528913	Benralizumab in Chronic Prurigo - Investigating Clinical Efficacy (BICPIC)	Drug: Fasenna Prefilled Syringe Other: Matching Placebo Solution	Charite University, Berlin, Germany	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05528913
NCT05671510	Study of Gotistobart (ONC-392/BNT316) vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer	Drug: Gotistobart Drug: Docetaxel	OncoC4, Inc. BioNTech SE	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05671510
NCT05878938	A Research Study Looking at How Safe it is to Switch From Emicizumab to Mim8 in People With Haemophilia A (FRONTIER 5)	Drug: NNC0365-3769 (Mim8) PPX	Novo Nordisk A/S	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05878938
NCT05733611	RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC	Biological: RP2 Biological: RP3 Biological: atezolizumab Biological: bevacizumab	Replimune Inc. Roche Pharma AG	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05733611

○ 중국 30건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05924997	Adebrelimab, Camrelizumab Plus Apatinib as First-line Therapy in Patients With Advanced Hepatocellular Carcinoma	Drug: adebrelimab, camrelizumab plus apatinib	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05924997
NCT05909098	Safety and Efficacy of Autologous NK Cell Adjuvant Therapy for Relapsed/Refractory Non-Hodgkin's B-cell Lymphoma	Combination Product: autologous NK cell	Xiangyang No.1 People's Hospital Qingdao Haier Biotechnology Co.,Ltd.	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05909098
NCT05832892	Surufatinib Combined With KN046 and AG Regimen Chemotherapy as First-Line Treatment for Unresectable Advanced Pancreatic Cancer	Drug: surufatinib Drug: KN046 Drug: gemcitabine Drug: Nab paclitaxel	Shanghai Zhongshan Hospital Fudan University	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05832892
NCT05785728	A Study of DB-1202 Monotherapy in Advanced Solid Tumors	Drug: DB-1202	DualityBio Inc.	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05785728
NCT05926427	Orelabrutinib Combined With Rituximab and Chemotherapy for Relapsed/Refractory B-Cell Lymphoma Patients With Central Nervous System Involvement	Drug: Orelabrutinib Drug: Rituximab Drug: Chemotherapy	Ruijin Hospital	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05926427
NCT05924841	A Study of BL-B01D1 Monotherapy and BL-B01D1+SI-B003 Combination Therapy in Patients With Extensive Stage Small Cell Lung Cancer	Drug: BL-B01D1 Drug: SI-B003	Sichuan Baili Pharmaceutical Co., Ltd.	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05924841
NCT05924373	Human Dental Pulp Mesenchymal Stem Cells for the Treatment of Chronic Periodontitis Patients	Drug: Human Dental Pulp Stem Cells	Peking University Third Hospital Capital Medical University	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05924373
NCT05924256	A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing	Drug: SHR-A1811 Drug: SHR 3680 + leuprolide Drug: SHR-A1921	Fudan University	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05924256

해외 바이오의약품 임상 현황 ('23년 6월 4주)

한국바이오의약품협회, 2023.07.04.

○ 중국 30건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05920876	A Study of QLS32015 in Patients With Recurrent or Refractory Multiple Myeloma	Drug: QLS32015	Qilu Pharmaceutical Co., Ltd.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05920876
NCT05920863	Lenvatinib Combined With Tislelizumab and TACE Applied as Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma With High-risk Recurrence Factors	Procedure: TACE Drug: Tislelizumab, Lenvatinib	Zhejiang Cancer Hospital	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05920863
NCT05919095	A Clinical Study of a Preoperative Translational Therapy for Unresectable Gallbladder Cancer	Drug: Carrilizumab plus GEMOX	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05919095
NCT05919030	A Study of Chemoradiation in Combination With Tislelizumab as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma	Radiation: Intensity-modulated radiotherapy (IMRT) Drug: Tislelizumab Drug: Cisplatin Drug: Nab paclitaxel	Renmin Hospital of Wuhan University	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05919030
NCT05912712	Autologous Platelet-rich Plasma (PRP) and Thrombin Coagulum for the Topical Treatment of Rectal Mucosal Ulcers	Other: Autologous Platelet-rich Plasma (PRP) and Thrombin Coagulum Treatment Other: Autologous Platelet-poor Plasma (PPP) and Thrombin Coagulum Treatment Drug: Mesalazine Suppository Treatment Biological: Infliximab Treatment	Xijing Hospital of Digestive Diseases	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05912712
NCT05912049	A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Properties and Immunogenicity of 9MW3811 in Healthy Subjects	Drug: 9MW3811 Injection Drug: Placebo	Mabwell (Shanghai) Bioscience Co., Ltd.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05912049
NCT05911984	A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Properties and Preliminary Efficacy of 9MW3811 in Patients With Advanced Solid Tumors	Drug: 9MW3811 Injection	Mabwell (Shanghai) Bioscience Co., Ltd.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05911984
NCT05896007	Zanubrutinib Combined With Rituximab and Chemotherapy for Newly-Diagnosed PCNSLCL Patients Intolerant to HSCT	Drug: Zanubrutinib Drug: Rituximab Drug: Methotrexate Drug: Temozolomide	Ruijin Hospital	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05896007
NCT05891561	Short-course Trastuzumab, Pertuzumab With Taxanes in the Adjuvant Treatment of Early HER2-positive Breast Cancer	Drug: Pertuzumab	Shanghai Jiao Tong University School of Medicine	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05891561
NCT05882370	TIPS Plus Cadonilimab in Advanced HCC With Tumor Thrombosis-associated Portal Hypertension:a Prospective, Single-arm, Phase II Study	Drug: Cadonilimab Procedure: transjugular intrahepatic portosystemic shunt (TIPS)	Fei Gao Sun Yat-sen University	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05882370
NCT05880706	A Study of BL-B01D1 Combined With Osimertinib Mesylate Tablets in Patients With Non-small Cell Lung Cancer	Drug: BL-B01D1 Drug: Osimertinib Mesylate Tablets	Sichuan Baili Pharmaceutical Co., Ltd.	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05880706
NCT05861778	Evaluation of 89Zr-TLX250 PET/CT in Chinese Patients With Indeterminate Renal Masses or Suspected Recurrent Renal Clear Cell Carcinoma	Drug: 89Zr-Girentuximab	Telix International Pty Ltd Grand Pharmaceutical (China) Co., Ltd.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05861778
NCT05843968	Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil in Children With Steroid-dependent Nephrotic Syndrome	Drug: Rituximab Drug: Mycophenolate Mofetil	Children's Hospital of Chongqing Medical University	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05843968

해외 바이오의약품 임상 현황 ('23년 6월 4주)

한국바이오의약품협회, 2023.07.04.

○ 중국 30건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05808673	Study of CMAB807X Pre- and Post-change in Manufacturing Site and Xgeva® in Healthy Volunteers	Biological: Post-change CMAB807X Biological: Pre-change CMAB807X Biological: Xgeva®	Taizhou Mabtech Pharmaceutical Co.,Ltd	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05808673
NCT05751187	Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients	Biological: Pembrolizumab Biological: Bevacizumab Drug: Pemetrexed Drug: Cisplatin Drug: Carboplatin Dietary Supplement: Folic acid 350-1000 µg Dietary Supplement: Vitamin B12 1000 µg Drug: Dexamethasone 4 mg	Shanghai Chest Hospital Merck Sharp & Dohme LLC	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05751187
NCT05663086	Immunogenicity and Safety of COVID-19 Vaccine in Population Aged 18 Years and Above	Biological: One dose group Biological: Two doses group Biological: Aged 18-59 years Biological: Aged 60 years old and above	Guangzhou Patronus Biotech Co., Ltd. Yantai Patronus Biotech Co., Ltd.	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05663086
NCT05562297	Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic Cancer	Drug: sintilimab Drug: nab-paclitaxel Drug: gemcitabine	Shanghai Zhongshan Hospital Fudan University	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05562297
NCT05904964	Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial)	Drug: Disitamab vedotin Other: Endocrine therapy	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05904964
NCT05901987	Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 2 Patients	Genetic: GC101	GeneCradle Inc	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05901987
NCT05845138	A Study of SHR-A1811 Combined With Capecitabine in Treatment of Unresectable or Metastatic Breast Cancer With Low HER2 Expression.	Drug: SHR-A1811 for injection ; capecitabine	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05845138
NCT05905133	A Study to Evaluate the Safety and Efficacy of CBP-201 in Chinese Adult Subjects With Moderate to Severe AD	Drug: CBP-201	Suzhou Connect Biopharmaceuticals, Ltd.	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05905133
NCT05904496	A Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-30813	Drug: BGB-30813 Drug: Tislelizumab	BeiGene	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05904496

○ 일본 2건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05832827	First-line CBDCA/PTX/LEN/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas (Artemis)	Drug: MK-3475 Drug: Lenvatinib Drug: Carboplatin Drug: Paclitaxel	National Cancer Center, Japan Merck Sharp & Dohme LLC	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05832827
NCT05878938	A Research Study Looking at How Safe it is to Switch From Emicizumab to Mim8 in People With Haemophilia A (FRONTIER 5)	Drug: NNC0365-3769 (Mim8) PPX	Novo Nordisk A/S	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05878938